FDA delays review of Epix' MRI (magnetic resonance imaging) agent appeal:
This article was originally published in Clinica
The US FDA has told Epix Pharmaceuticals that it will delay until September the completion of a review of the firm's appeal regarding its magnetic resonance imaging (MRI) vascular contrast agent, Vasovist. The appeal concerns two previously-issued FDA approvable letters for the product, one of which requested that at least one additional trial be performed before the product could be sanctioned. It was lodge by the Cambridge, Massachusetts firm on June 30 2006, and asks that the agency approve Vasovist and use an advisory committee as part of the appeal process (see Clinica No 1213, p 19).
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.